Inheritance of a Novel COL8A2 Mutation Defines a Distinct Early-Onset Subtype of Fuchs Corneal Dystrophy


PURPOSE. To characterize the genetic basis and phenotype of inherited Fuchs corneal dystrophy (FCD).

METHODS. DNA from blood was used for genome-wide linkage scans with tandem repeat polymorphisms. Mutation detection involved sequencing PCR-amplified exons. Families with FCD were clinically evaluated and graded on the Krachmer severity scale. Confocal specular microscopy visualized the morphology of endothelial guttae, small protrusions of Descemet’s membrane that are characteristic of FCD.

RESULTS. Linkage was obtained to 1p34.3-p32 for the autosomal dominant kindred originally reported by Magovern in 1979. All 21 cases with FCD and one with posterior polymorphous dystrophy were heterozygous for L450W, a novel point mutation in the COL8A2 gene. Of 62 independent cases of familial FCD, none had the previously reported mutations in COL8A2. Corneal guttae in COL8A2 patients were small, rounded, and associated with the endothelial cell center. This contrasts with common FCD, in which guttae were larger, sharply peaked, and initially positioned at edges of endothelial cells. The profile of age and disease severity for the L450W FCD kindred suggested that disease onset occurred in infancy, compared with an average age of onset of 50 years estimated for 201 familial FCD patients in 62 other families.

CONCLUSIONS. A novel pathogenic L450W COL8A2 mutation was identified and its highly distinctive pathology characterized. This indicates that COL8A2 mutations give rise to a rare subtype of FCD. This study also provides the first direct evidence that COL8A2-FCD progresses from early to late stages in 25 years, a rate similar to that estimated for late-onset FCD.

(FInvest Ophthalmol Vis Sci. 2005;46:1934–1939) DOI: 10.1167/iovs.04-0937

From the 1Center for Corneal Genetics, Cornea and External Disease Service, the 2Laboratory of Developmental Genetics, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; and the 3Department of Molecular Biology and Genetics, and the 4Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Supported by The Josephine S. Sutland and the Shelia S. and Dr. Lawrence C. Pakula Research Fund, and The Commonwealth Research Fund.

Submitted for publication August 3, 2004; revised November 5, 2004; accepted December 10, 2004.

Disclosure: J.D. Gottsch, None; O.H. Sundin, None; S.H. Liu, None; A.S. Jun, None; K.W. Broman, None; W.J. Stark, None; E.C.L. Vito, None; A.K. Narang, None; J.M. Thompson, None; M. Magovern, None

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked ‘advertisement’ in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: John D. Gottsch, The Wilmer Eye Institute, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD 21287; jgottsch@jhmi.edu.

Fuchs corneal dystrophy (FCD) is a primary disorder of the endothelium that leads to progressive edema of the corneal stroma (OMIM 136800; Online Mendelian Inheritance in Man; http://www.ncbi.nlm.nih.gov/Omim/provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD). Visual disability from this disease is currently the major reason for corneal transplantation.1 The initial stages of FCD typically begin in the fifth through seventh decades of life and are characterized by localized thickening of Descemet’s membrane and the development of nodular excrescences called guttae. This early phase is followed by long-term decreases in the density and ion transport functions of the overlying corneal endothelial cells, which allows excess water to accumulate in the cornea.2–8 Several reports, including the original description by Fuchs, have indicated that two to three times as many females as males are affected by the disease.2,7,9

As many as 50% of clinical cases of FCD may show familial clustering,5 and the disease generally follows an autosomal dominant pattern of inheritance.10–15 Nearly all these families show inheritance of late-onset FCD, whereas rare cases12,14 show disease onset as early as the first decade, with extensive corneal edema by the third or fourth decades. Recently, a multigenerational family exhibiting advanced FCD by their third and fourth decades revealed genetic linkage to a 7 cM region of chromosome 1p34.3-p32.14 Individuals affected with FCD were found to be heterozygous for a point mutation altering the collagen helix domain of the α2 chain of type VIII collagen (COL8A2), substituting a lysine for a glutamine (Q455K). Because collagen VIII is a major component of Descemet’s membrane, the mutation provides important evidence that the disease originates as a molecular dysfunction of the extracellular matrix of the endothelium. A second independently ascertained, large family, also described as having early onset, had exactly the same Q455K mutation.14 This second family showed perfect concordance between the mutation and individuals affected with FCD. In a third independent small family,14 the Q455K mutation was associated with two patients with posterior polymorphous corneal dystrophy (PPCD), a distinct endothelial cell disorder with some features similar to FCD. To date, no COL8A2 amino acid sequence variants have been identified that are clearly associated with late-onset FCD.16 We have performed genetic linkage analysis of the large early-onset FCD family originally described by Magovern et al.,12 and identified a second COL8A2 mutation, L450W. We report that this mutation is associated with highly distinctive guttae that differ from those of common late-onset FCD and suggest that mutations in COL8A2 give rise to a rare subtype of FCD. Long-term study of this family has also provided us with the unique opportunity to follow the temporal progression of inherited FCD.

MATERIALS AND METHODS

Families

A total of 63 families were recruited after initial evaluations of patients with FCD at the Cornea Service of the Wilmer Ophthalmological
Severe grading, photography, and confocal specular microscopy

Patients were photographed to demonstrate the area and number of confluent guttae by direct, indirect, and retroillumination. Grading was based on the extent and pattern of guttae. Grade 1, initial appearance of central, nonconfluent guttae in at least one eye; grade 2, a zone of central, nonconfluent guttae 1 to 2 mm in width; grade 3, a greater than 2-to-5 mm wide zone of confluent guttae in the central cornea; grade 4, a central region of confluent guttae greater than 5 mm in width; and grade 5, the same as grade 4, but with added disease involving stromal or epithelial edema. Confocal specular microscopy was used to visualize the guttae in Descemet's membrane and to obtain an en face image of endothelial cells.

Genotyping and linkage analysis

Venous blood (10 mL) was collected and frozen at ~20°C. DNA was extracted using standard methods (Qiagen, Santa Clara, CA). Genotyping of polymorphic linkage markers was performed at the University of Utah Genomics Core Facility (Salt Lake City, UT; http://www.cores.utah.edu/genomics/index.htm). Genome-wide scans were performed with fluorescently labeled primers of the MD10 microsatellite marker set (Applied Biosystems Inc. [ABI], Foster City, CA). Standard PCR conditions (ABI) were used, and products were ethanol precipitated and electrophoresed through 5% polyacrylamide gels on an automated DNA sequencer (Prism 377; ABI). GC melt (final concentration of 1.0 M) was added to PCR reactions to alleviate secondary-structure problems created by the very high GC content of COL8A2. The PCR conditions were as follows: initial denaturation (95°C, 1 minute) followed by 35 cycles of denaturation (94°C, 30 seconds), annealing (62.0°C for primer 12, 30 seconds), and extension (72°C, 90 seconds) followed by final extension (72°C, 10 minutes). PCR products were purified (Qiaquick columns; Qiagen) and directly analyzed on an automated DNA sequencer (Prism 377; ABI). Nucleotide sequences were compared with the published cDNA sequence of the COL8A2 gene by BLAST search.

Mutation screening of COL8A2

Genomic DNA was purified as above and exons of the COL8A2 gene PCR amplified with the 16 sets of primer pairs used in earlier work. The PCRs were performed with the GC-genomic polymerase system (BD Biosciences, Palo Alto, CA) in a total volume of 50 μL using 100 ng of each genomic DNA sample as templates. GC melt (final concentration of 1.0 M) was added to PCR reactions to alleviate secondary-structure problems created by the very high GC content of COL8A2. The PCR conditions were as follows: initial denaturation (95°C, 1 minute) followed by 35 cycles of denaturation (94°C, 30 seconds), annealing (62°C for primer 12, 30 seconds), extension (72°C, 90 seconds), and final extension (72°C, 5 minutes). PCR products were purified (Qiaquick columns; Qiagen) and directly analyzed on an automated DNA sequencer (Prism 377; ABI). Nucleotide sequences were compared with the published cDNA sequence of the COL8A2 gene by BLAST search.

Age, sex, and severity of disease in families with FCD

Families with and without COL8A2 mutations were compared as to age, sex, and severity of disease. The statistical significance of the observed earlier onset of Fuchs in the Magovern pedigree was assessed by comparing the average age of individuals with severity of grade 3 or greater in this pedigree versus other pedigrees. The statistical significance of the difference in sex ratios among affected individuals (with severity ≥ 1) in the Magovern pedigree versus other pedigrees was assessed by the Fisher exact test.

Results

Genetic linkage and mutation screen

The pedigree (Fig. 1) was analyzed by testing 17 affected and 5 unaffected family members with microsatellite markers. These covered all 22 autosomes, with an average spacing of 10 centimorgans (cM). Multipoint linkage analysis identified a 22-Mb disease interval between DIS234 and DIS2797 on
1p35-p33.1. This had a maximum LOD score of 3.65 at marker D1S255, located 1 cM from the COL8A2 gene, which was screened for mutations. This revealed a transversion mutation that changed leucine to tryptophan (TTG to TGG) at residue 450, located in the collagen repeat domain of the COL8A2 protein. In this family, the mutant allele was always associated with the disease phenotype and was not found in unaffected relatives or spouses. The allele was not found in 112 background-matched, normal, white control subjects (224 chromosomes). None of the four previously reported pathogenic mutations of COL8A2 (Arg155Gln, Arg304Gln, Arg434His, and Gln455Lys) were found in probands from each of the 62 families with late-onset disease.

**Corneal Slit Lamp Photography and Confocal Specular Microscopy of Fuchs Families with COL8A2 and Non-COL8A2 Mutations**

Retroillumination of the cornea in representative patients with the COL8A2 mutation revealed a fine, patchy distribution of guttae in contrast to patients with late-onset FCD, in whom the guttae were more coarse and distinct. Areas of coalescence were evident with intervening nonaffected areas (Fig. 2A, 2B). Confocal specular microscopy of the endothelium in patients with the L450W-COL8A2 mutation demonstrated mildly elevated guttae that were associated with individual endothelial cells (Fig. 3A). One patient with the L450W-COL8A2 mutation exhibited endothelial anomalies characteristic of posterior polymorphous dystrophy (Fig. 4). In contrast, familial late-onset FCD patients had typical guttae, which were sharply raised and typically located along the borders between endothelial cells (Fig. 3B).

**Age-Severity Profile of Families with FCD**

Figure 5 displays the association between age and severity among affected individuals. The average age of severely affected patients, those of grade 3 or greater, was roughly 40 years younger for the COL8A2 pedigree (Fig. 5, filled symbols) than for patients in the remaining 62 families. Comparing the ages of patients of grade 3 and higher from the currently examined affected members of the Magovern pedigree (without parentheses) with the ages of other familial cases in the same severity range, we can establish the significance of early onset with a high level of confidence ($P = 5 \times 10^{-3}$).

The COL8A2 pedigree, in which some patients were reexamined after 25 to 29 years, also provides direct data on progression. Figure 5 represents two girls at severity grade 1,
who were aged 3 and 4 years (Fig. 1; filled circles with brackets, open and filled arrows in Fig. 1) when examined in 1974, and progressed to grades 4 and 5 over the next 29 years. The dotted line connecting their 1974 and 2003 symbols gives a minimal increase of one severity grade every 8 years. Disease progression in these two individuals proceeded at a rate that closely follows the age versus severity distribution of the static data points, roughly 1 grade unit per 5 years (Fig. 5, filled symbols).

For the more heterogeneous patients with late-onset FCD (Fig. 5, open symbols) graphing the mean ages for each severity group indicates that the average age of the patients advances 5 years as one moves up each severity grade. This is surprisingly similar to the age-versus-severity relationship observed in the patients with early-onset disease bearing L450W-COL8A2, although median age of onset for this group is at least 40 years later. Another interesting feature of the graph is that the mean age of each severity grade follows a linear progression for both early and late disease. The definitions of the standard severity grading system of Krachmer et al.9 may have been selected to give a similar fraction of the total patient population in each grade, which would have normalized the results toward a linear profile. Finally, it should be noted that the two open symbols at ages 10 and 13 years are members of a single large kindred segregating late-onset FCD. They represent a special case, in that for each child, both parents were affected with late-onset FCD, and the morphology of their guttae was typical of late-onset disease.

**Sex Ratios of Patients with FCD**

Table 1 compares the sex distribution within the COL8A2 pedigree with that of 62 other familial FCD pedigrees. Both affected individuals and total members of the COL8A2 pedigree approximated a 1:1 female-male ratio, whereas affected individuals in the late-onset pedigrees were approximately 2.5:1. This excess of females in the 62 other pedigrees cannot be explained by chance variations of an underlying 1:1 ratio ($P < 0.01$) and confirms earlier findings for the general patient population.2,9 Conversely, the observed female-male ratio of 12:14 among affected members of the L450W-COL8A2 pedigree is very unlikely to fit a 2.5:1 ratio ($P < 0.01$), or in a 2:1 ratio ($P < 0.03$).

**DISCUSSION**

In a large family with early-onset FCD,12 we have identified a mutation in the gene that encodes the $\alpha$-2 chain of collagen VIII, a major component of Descemet’s membrane. This COL8A2 point mutation, L450W, segregates with the disease as a dominant mutant at 100% penetrance. Our finding is of importance because this is only the second linkage-confirmed mutation reported for FCD. We also discovered that patients in this pedigree are very distinct from those with common forms of FCD in both morphologic features and temporal progression of the disease and suggest that this and the previously reported Q455K-COL8A2 mutations are associated with a rare early-onset subtype of FCD. Although the COL8A2 variants R155Q, R304Q, and R434H were originally found in late-onset FCD and have been presented as evidence that this gene is also involved in common forms of the disease,13 recent evidence indicates that R155Q is found at the same frequency in normal control subjects and is therefore unlikely to be pathogenic.16 There have been no further reports that implicate R304Q or R434H in FCD, and the pathogenicity of these variants is also unconfirmed. Without strong linkage data or evidence of defects in
biochemical function, it not easy to make a case that amino acid substitutions cause a disease, as benign variants are the most common and can vary widely in frequency between different populations.

Morphologic Features
We have shown that guttae in the L450W-COL8A2-carrying patients have a structure and distribution that differs considerably from that of patients with common late-onset FCD. Although there was no discussion of the morphology of guttae in the earlier report on the Q455K-COL8A2 mutation, it presented a confocal micrograph (see Fig. 3B of Reference 14) of guttae with morphology strikingly similar to those in the L450W-COL8A2-bearing patients. The Q455K-COL8A2 patient also had small, shallow guttae positioned near the center of the endothelial cells. It is of interest whether these features are a general feature of FCD-causing mutations in COL8A2. The mechanism by which COL8A2 mutations lead to the formation and positioning of guttae may be slightly different from that in late-onset disease, in which the guttae generally appear first at cell–cell junctions, near the basolateral face of the endothelial cells.

Another finding shared between the L450W and Q455K-COL8A2 mutations is the sporadic diagnosis of PPCD (OMIM 122000). This condition involves the development of vesicles with the epithelial transformation of endothelial cells. It is usually not progressive but can be accompanied by corneal decompensation. In a rare hereditary form of PPCD that has been mapped to 20q11, endothelial cell proliferation can occlude aqueous outflow. FCD is distinguished from PPCD by the fact that it lacks these vesicles and the endothelium retains its histologic character. In one 12-year-old L450W-COL8A2 patient with PPCD, we found highly characteristic mulberry-like vesicles. There were no signs of guttae outside the vesicles, which supports the interpretation that this may be an alternate disease course. It is possible that this single patient in the pedigree had genetic or environmental modifying factors.

Early-Onset and Homogeneity of Disease Progression
With the L450W-COL8A2 mutation, children as young as 3 years have been found to be affected. All who were in the early stages of the disease at the time of the 1979 study have since progressed to corneal decompensation, and several have undergone penetrating keratoplasty. This natural history fits well with earlier reports of the Q455K-COL8A2 mutation, in which FCD was diagnosed in individuals from ages 21 to 48, and those in their 30s and 40s had advanced stages of disease. Because no member of the Q455K family appears to have been screened for very early stages of the disease, it cannot be ruled out that some were affected as early as age 3.

A unique feature of the L450W family is that we have been able to combine data collected in the 1970s with recent examinations of the same individuals, as well as to ascertain new patients. In some cases, disease severity was graded at the time of corneal transplantation. The age-versus-severity distribution of the L450W-COL8A2-carrying patients is much narrower than that of the other 201 patients with late-onset disease. This is not unexpected, because the late-onset group very likely involved great heterogeneity, both in the genes involved and the severity of the specific mutations.

The Sex Ratio
In the L450W-COL8A2 family, the ratio of females to males was roughly 1:1, as originally noted in 1979. What is new is that there are now enough individuals to show that, statistically, this number is not compatible with the 2:1 or 3:1 female-male ratios long observed for clinical cases of FCD. For the broader patient population we confirm earlier findings of a 2.5:1 female-male ratio for a group of 201 familial patients with late-onset FCD. What is clear is that the Mendelian COL8A2 mutation follows conventional expectations of a 1:1 ratio, and does not conform to the peculiar 2.5:1 ratio of common FCD. Among those older than 50 years, the greater longevity of women is expected to give a female-male ratio that is between 1.2:1 and 1.3:1, a range that is insufficient to explain the 2.5:1 distribution in FCD.

Disease Mechanisms
How mutations in the COL8A2 gene cause the clinical and histopathological features of FCD or PPCD remains unknown. Collagen VIII is a short-chain, nonfibrillar, extracellular matrix component with a composition that varies between tissues and there is evidence that it may serve a structural role or be involved in cellular differentiation. In FCD, it appears to accumulate at higher levels within Descemet's membrane in the posterior collagenous zone, which appears to contribute structurally to the guttae. The α1 and α2 chains of collagen VIII assemble in vivo as trimers by their collagen helix domains, and form a hexagonal lattice. The subunit composition of these trimers within the lattice remains unknown, as does the relationship of the lattice structure itself to the biological functions of Descemet's membrane. Because collagen VIII is also produced by vascular endothelial cells, one would expect a mutation that destroyed the basic functions of the COL8A2 protein to have severe and systemic effects that were not seen in these patients with FCD in our study. Our discovery of a second FCD-related dominant mutation affecting a small, conserved interval of the COL8A2 collagen helix domain suggests that this region may be of selective importance to the function of this protein in the cornea, as these mutations have no obvious effects elsewhere in the body.

We suggest two very different disease mechanisms. First, genetically abnormal collagen VIII may interfere with cell adhesion and differentiation of the endothelium, as in PPCD. In FCD, it is possible that mutant COL8A2 proteins improperly interact with other molecules in the extracellular matrix, resulting in sites of structural weakness in Descemet's membrane that allow the extrusion of material that forms the guttae. The irregular basal lamina topography appears to indent physically and stretch the endothelial cells, which may compromise their ability to transport electrolytes and maintain corneal clarity.

References


